No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

1. Polman, CH, O’Connor, PW, Havrdova, E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.
Google Scholar | Crossref | Medline | ISI2. Perumal, J, Fox, RJ, Balabanov, R, et al. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol 2019; 19: 116–127.
Google Scholar | Crossref | Medline3. Butzkueven, H, Kappos, L, Wiendl, H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 2020; 91: 660–668.
Google Scholar | Crossref | Medline4. Bigaut, K, Fabacher, T, Kremer, L, et al. Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. Mult Scler 2020; 27: 729–741.
Google Scholar | SAGE Journals5. Bloomgren, G, Richman, S, Hotermans, C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.
Google Scholar | Crossref | Medline | ISI6. Ho, P-R, Koendgen, H, Campbell, N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 2017; 16: 925–933.
Google Scholar | Crossref | Medline7. Zhovtis Ryerson, L, Frohman, TC, Foley, J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 885–889.
Google Scholar | Crossref | Medline | ISI8. Yamout, BI, Sahraian, MA, Ayoubi, NE, et al. Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord 2018; 24: 113–116.
Google Scholar | Crossref | Medline9. Zhovtis Ryerson, L, Foley, J, Chang, I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 2019; 93: e1452–e1462.
Google Scholar | Medline10. Bomprezzi, R, Pawate, S. Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord 2014; 7: 227–231.
Google Scholar | SAGE Journals | ISI11. Clerico, M, De Mercanti, SF, Signori, A, et al. Extending the interval of natalizumab dosing: is efficacy preserved? Neurotherapeutics 2020; 17: 200–207.
Google Scholar | Crossref | Medline12. Butzkueven, H, Kappos, L, Pellegrini, F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85: 1190–1197.
Google Scholar | Crossref | Medline | ISI13. Austin, PC . Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011; 10: 150–161.
Google Scholar | Crossref | Medline | ISI14. Belachew, S, Phan-Ba, R, Bartholomé, E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2011; 18: 240–245.
Google Scholar | Crossref | Medline | ISI15. Melin, A, Outteryck, O, Collongues, N, et al. Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol 2012; 259: 1215–1221.
Google Scholar | Crossref | Medline | ISI16. Totaro, R, Lugaresi, A, Bellantonio, P, et al. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. Int J Immunopathol Pharmacol 2014; 27: 147–154.
Google Scholar | SAGE Journals | ISI17. Chisari, CG, Grimaldi, LM, Salemi, G, et al. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2020; 91: 1297–1303.
Google Scholar | Crossref | Medline18. Muralidharan, KK, Steiner, D, Amarante, D, et al. Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis. J Pharmacokinet Pharmacodyn 2017; 44: 263–275.
Google Scholar | Crossref | Medline19. Chang, I, Muralidharan, KK, Campbell, N, et al. Modeling the efficacy of natalizumab in multiple sclerosis patients who switch from every-4-week dosing to extended-interval dosing. J Clin Pharmacol 2021; 61: 339–348.
Google Scholar | Crossref | Medline20. Baldassari, LE, Jones, SE, Clifford, DB, et al. Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurol Clin Pract 2018; 8: e12–e14.
Google Scholar | Crossref | Medline21. Scarpazza, C, De Rossi, N, Tabiadon, G, et al. Four cases of natalizumab-related PML: a less severe course in extended interval dosing? Neurol Sci 2019; 40: 2119–2124.
Google Scholar | Crossref | Medline22. Hervás, JV, Presas-Rodríguez, S, Crespo-Cuevas, AM, et al. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen. Neurodegener Dis Manag 2015; 5: 399–402.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif